Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

M. P. Manns, P. J. Pockros, G. Norkrans, C. I. Smith, T. R. Morgan, D. Häussinger, M. L. Shiffman, S. J. Hadziyannis, W. N. Schmidt, I. M. Jacobson, R. Bárcena, Eugene R Schiff, O. S. Shaikh, B. Bacon, P. Marcellin, W. Deng, R. Esteban-Mur, T. Poynard, L. D. Pedicone, C. A. BrassJ. K. Albrecht, S. C. Gordon

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follow-up studies of patients previously treated for CHC in eight prospective randomized studies of IFN α-2b and/or PEG-IFN α-2b. Patients who achieved SVR [undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of treatment] were eligible for inclusion in these follow-up studies. In total, 636 patients with SVR following treatment with IFN α-2b and 366 with SVR following treatment with PEG-IFN α-2b were enrolled. Definite relapse (quantifiable serum HCV RNA with no subsequent undetectable HCV RNA) was reported in six patients treated with IFN α-2b and three patients treated with PEG-IFN α-2b. Based on these relapses, the point estimate for the likelihood of maintaining response after 5 years was 99.2% [95% confidence interval (CI), 98.1-99.7%] for IFN α-2b and 99.4% (95% CI, 97.7-99.9%) for PEG-IFN α-2b. Successful treatment of hepatitis C with PEG-IFN α-2b or IFN α-2b leads to clinical cure of hepatitis C in the vast majority of cases.

Original languageEnglish
Pages (from-to)524-529
Number of pages6
JournalJournal of Viral Hepatitis
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2013

Fingerprint

Ribavirin
Hepacivirus
Interferons
Chronic Hepatitis C
RNA
Hepatitis C
Confidence Intervals
Therapeutics
Recurrence
Sustained Virologic Response
Prospective Studies
Serum

Keywords

  • clinical
  • cure
  • eradication
  • follow-up
  • longitudinal

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger, D., ... Gordon, S. C. (2013). Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. Journal of Viral Hepatitis, 20(8), 524-529. https://doi.org/10.1111/jvh.12074

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. / Manns, M. P.; Pockros, P. J.; Norkrans, G.; Smith, C. I.; Morgan, T. R.; Häussinger, D.; Shiffman, M. L.; Hadziyannis, S. J.; Schmidt, W. N.; Jacobson, I. M.; Bárcena, R.; Schiff, Eugene R; Shaikh, O. S.; Bacon, B.; Marcellin, P.; Deng, W.; Esteban-Mur, R.; Poynard, T.; Pedicone, L. D.; Brass, C. A.; Albrecht, J. K.; Gordon, S. C.

In: Journal of Viral Hepatitis, Vol. 20, No. 8, 01.08.2013, p. 524-529.

Research output: Contribution to journalArticle

Manns, MP, Pockros, PJ, Norkrans, G, Smith, CI, Morgan, TR, Häussinger, D, Shiffman, ML, Hadziyannis, SJ, Schmidt, WN, Jacobson, IM, Bárcena, R, Schiff, ER, Shaikh, OS, Bacon, B, Marcellin, P, Deng, W, Esteban-Mur, R, Poynard, T, Pedicone, LD, Brass, CA, Albrecht, JK & Gordon, SC 2013, 'Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin', Journal of Viral Hepatitis, vol. 20, no. 8, pp. 524-529. https://doi.org/10.1111/jvh.12074
Manns, M. P. ; Pockros, P. J. ; Norkrans, G. ; Smith, C. I. ; Morgan, T. R. ; Häussinger, D. ; Shiffman, M. L. ; Hadziyannis, S. J. ; Schmidt, W. N. ; Jacobson, I. M. ; Bárcena, R. ; Schiff, Eugene R ; Shaikh, O. S. ; Bacon, B. ; Marcellin, P. ; Deng, W. ; Esteban-Mur, R. ; Poynard, T. ; Pedicone, L. D. ; Brass, C. A. ; Albrecht, J. K. ; Gordon, S. C. / Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. In: Journal of Viral Hepatitis. 2013 ; Vol. 20, No. 8. pp. 524-529.
@article{4ac8f6bceb28438f8664dda52a3ce4d0,
title = "Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin",
abstract = "Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follow-up studies of patients previously treated for CHC in eight prospective randomized studies of IFN α-2b and/or PEG-IFN α-2b. Patients who achieved SVR [undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of treatment] were eligible for inclusion in these follow-up studies. In total, 636 patients with SVR following treatment with IFN α-2b and 366 with SVR following treatment with PEG-IFN α-2b were enrolled. Definite relapse (quantifiable serum HCV RNA with no subsequent undetectable HCV RNA) was reported in six patients treated with IFN α-2b and three patients treated with PEG-IFN α-2b. Based on these relapses, the point estimate for the likelihood of maintaining response after 5 years was 99.2{\%} [95{\%} confidence interval (CI), 98.1-99.7{\%}] for IFN α-2b and 99.4{\%} (95{\%} CI, 97.7-99.9{\%}) for PEG-IFN α-2b. Successful treatment of hepatitis C with PEG-IFN α-2b or IFN α-2b leads to clinical cure of hepatitis C in the vast majority of cases.",
keywords = "clinical, cure, eradication, follow-up, longitudinal",
author = "Manns, {M. P.} and Pockros, {P. J.} and G. Norkrans and Smith, {C. I.} and Morgan, {T. R.} and D. H{\"a}ussinger and Shiffman, {M. L.} and Hadziyannis, {S. J.} and Schmidt, {W. N.} and Jacobson, {I. M.} and R. B{\'a}rcena and Schiff, {Eugene R} and Shaikh, {O. S.} and B. Bacon and P. Marcellin and W. Deng and R. Esteban-Mur and T. Poynard and Pedicone, {L. D.} and Brass, {C. A.} and Albrecht, {J. K.} and Gordon, {S. C.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1111/jvh.12074",
language = "English",
volume = "20",
pages = "524--529",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

AU - Manns, M. P.

AU - Pockros, P. J.

AU - Norkrans, G.

AU - Smith, C. I.

AU - Morgan, T. R.

AU - Häussinger, D.

AU - Shiffman, M. L.

AU - Hadziyannis, S. J.

AU - Schmidt, W. N.

AU - Jacobson, I. M.

AU - Bárcena, R.

AU - Schiff, Eugene R

AU - Shaikh, O. S.

AU - Bacon, B.

AU - Marcellin, P.

AU - Deng, W.

AU - Esteban-Mur, R.

AU - Poynard, T.

AU - Pedicone, L. D.

AU - Brass, C. A.

AU - Albrecht, J. K.

AU - Gordon, S. C.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follow-up studies of patients previously treated for CHC in eight prospective randomized studies of IFN α-2b and/or PEG-IFN α-2b. Patients who achieved SVR [undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of treatment] were eligible for inclusion in these follow-up studies. In total, 636 patients with SVR following treatment with IFN α-2b and 366 with SVR following treatment with PEG-IFN α-2b were enrolled. Definite relapse (quantifiable serum HCV RNA with no subsequent undetectable HCV RNA) was reported in six patients treated with IFN α-2b and three patients treated with PEG-IFN α-2b. Based on these relapses, the point estimate for the likelihood of maintaining response after 5 years was 99.2% [95% confidence interval (CI), 98.1-99.7%] for IFN α-2b and 99.4% (95% CI, 97.7-99.9%) for PEG-IFN α-2b. Successful treatment of hepatitis C with PEG-IFN α-2b or IFN α-2b leads to clinical cure of hepatitis C in the vast majority of cases.

AB - Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follow-up studies of patients previously treated for CHC in eight prospective randomized studies of IFN α-2b and/or PEG-IFN α-2b. Patients who achieved SVR [undetectable hepatitis C virus (HCV) RNA 24 weeks after completion of treatment] were eligible for inclusion in these follow-up studies. In total, 636 patients with SVR following treatment with IFN α-2b and 366 with SVR following treatment with PEG-IFN α-2b were enrolled. Definite relapse (quantifiable serum HCV RNA with no subsequent undetectable HCV RNA) was reported in six patients treated with IFN α-2b and three patients treated with PEG-IFN α-2b. Based on these relapses, the point estimate for the likelihood of maintaining response after 5 years was 99.2% [95% confidence interval (CI), 98.1-99.7%] for IFN α-2b and 99.4% (95% CI, 97.7-99.9%) for PEG-IFN α-2b. Successful treatment of hepatitis C with PEG-IFN α-2b or IFN α-2b leads to clinical cure of hepatitis C in the vast majority of cases.

KW - clinical

KW - cure

KW - eradication

KW - follow-up

KW - longitudinal

UR - http://www.scopus.com/inward/record.url?scp=84879795584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879795584&partnerID=8YFLogxK

U2 - 10.1111/jvh.12074

DO - 10.1111/jvh.12074

M3 - Article

C2 - 23808990

AN - SCOPUS:84879795584

VL - 20

SP - 524

EP - 529

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 8

ER -